Kees Hovingh Articles
ISA 2015: PCSK9 inhibitors effective in mixed dyslipidaemia
Treatment with evolocumab or alirocumab was as effective in high risk patients with mixed dyslipidaemia, as in patients solely with elevated low-density lipoprotein (LDL) cholesterol, according to two reports at ISA 2015. Dr Kees Hovingh, Academic Medical Center, Amsterdam, the Netherlands discussed data from an…
read more »Posted on 1 June 2015 |
Posted by Kees Hovingh | Posted in News,
17th International Symposium on Atherosclerosis 2015
FH – the challenges for the next 10 years?
Kees Hovingh, Academic Medical Center, Amsterdam, the Netherlands In a session on familial hypercholesterolaemia (FH, inherited high cholesterol) at the 83rd Annual Congress of the European Atherosclerosis Society (EAS), Dr Kees Hovingh outlined what he saw as the challenges for FH in the next decade….
read more »Posted on 16 April 2015 |
Posted by Kees Hovingh | Posted in From the Editors,
83rd Congress of the European Atherosclerosis Society 2015
